LAS VEGAS, Dec. 10, 2024 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTC: BDPT) is thrilled to announce the launch of Xcellara™ Stem Cell Activator, a groundbreaking supplement that harnesses ...
Stem cell therapy shows promise for silicosis by targeting fibrosis, immune imbalance, and lung function decline.
Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of allogeneic mesenchymal stem cell therapies for diabetic ...
Xcellara™ Stem Cell Activator has been scientifically shown to significantly increase circulating stem cells in humans, dogs, horses, and other mammals. Stem cells foster cellular regeneration and ...